Karyopharm Therapeutics Inc. (KPTI)
Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.
Sector: Pharmaceutical Preparations
Industry: Biotechnology
Karyopharm Therapeutics Inc.
- 38.2%
- 8.2M
- 1.09
Float 21.53M · Signal8 dilution snapshot · Aug 13, 2026
The cost to borrow KPTI shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.
- 48.8%
- 362.5K
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
Latest short interest settlements (today's share basis)
| Date | Shares short |
|---|---|
| Oct 30, 2026 | 8.2M sh |
| Oct 15, 2026 | 7.3M sh |
| Sep 30, 2026 | 6.1M sh |
| Sep 15, 2026 | 7.9M sh |
| Aug 31, 2026 | 9.8M sh |
Latest fails to deliver
| Date | Shares failed |
|---|---|
| Oct 30, 2026 | 362.5K sh |
| Oct 29, 2026 | 766.7K sh |
| Oct 28, 2026 | 2.7K sh |
| Oct 27, 2026 | 17.8K sh |
| Oct 26, 2026 | 126.5K sh |
The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.
Latest sessions
| Date | Reported short |
|---|---|
| Nov 10, 2026 | 48.8% |
| Nov 9, 2026 | 52.4% |
| Nov 6, 2026 | 50.0% |
| Nov 5, 2026 | 39.0% |
| Nov 4, 2026 | 43.7% |
130 calendar days requested; 87 sessions published. FINRA reports this at T+1 to T+2, so the latest session is not today's.
Source: FINRA Reg SHO daily short volume, summed across the NASDAQ, NYSE and Consolidated trade reporting facilities. Covers off-exchange (over-the-counter) executions only; volume executed on an exchange is not included and is not reported short here.
Off-exchange short volume is not short interest and is not a bearish signal. When a wholesaler fills a retail buy order it sells to the customer as principal and buys back in the market, and that sale is reported as short. A high reported short share is therefore characteristic of internalised retail buying, and this figure should not be read as investors positioning against the stock.
FINRA's weekly alternative trading system (dark pool) volume for KPTI: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.
As of the Oct 30, 2026 FINRA settlement, 8,232,156 KPTI shares were sold short (38.23% of a 21.53M-share float, 1.09 days to cover).